履歷(教育及工作經驗)
教育：
2013 北京大學 藥學學士
2015北京大學 藥物化學碩士
2019 北京大學 藥物化學博士
工作經驗：
1. 2019-2020 副研究員 福建醫科大學孟超肝膽醫院
2. 2020-2022 博士後 香港浸會大學中醫藥學院
3. 2022-2025 研究助理教授 香港浸會大學中醫藥學院
4. 2025-至今研究助理教授 香港中文大學中醫學院
科研範圍：
1. 適配體功能化中藥抗腫瘤領域研究
2. 基於靶向蛋白降解技術的中藥組分開發
著作及論文（選列）：
1. Amu Gubu, Yang Xin, Luo Hang, Yu Sifan, Zhang Huarui, Tian Yuan, Yu Yuanyuan, Ding Shijian, Pan Yufei, Chen Zefeng, He Yixin, Ma Yuan (co-first author & co-corresponding author), Zhang Baoting, Zhang Ge. Machine learning-powered, high-affinity modification strategies for aptamers. Acta Materia Medica 2025, 4 (1), 122-136. DOI: 10.15212/amm-2024-0065
2. Shen Xinyang, Ma Yuan (co-first author), Luo Hang, Abdullah Razack, Pan Yufei, Zhang Yihao, Zhong Chuanxin, Zhang Baoting, Zhang Ge. Peptide Aptamer-Paclitaxel Conjugates for Tumor Targeted Therapy. Pharmaceuticals 2025, 17, 40. DOI: 10.3390/pharmaceutics17010040
3. Ma Yuan, Zhang Huarui, Shen Xinyang, Yang Xin, Deng Yan, Tian Yuan, Chen Zefeng, Pan Yufei, Luo Hang, Zhong Chuanxin, Yu Sifan, Lu Aiping, Zhang Baoting, Tang Tao, Zhang Ge. Aptamer Functionalized Hypoxia-potentiating Agent and Hypoxia-inducible Factor Inhibitor Combined with Hypoxia-activated Prodrug for Enhanced Tumor Therapy. Cancer Letters 2024, 598, 217102. DOI: 10.1016/j.canlet.2024.217102
4. Amu Gubu, Zhang Ge, Jing Nanan, Ma Yuan. Developing Stapled Aptamers with a Constrained Conformation for Osteogenesis Imperfect Therapeutics. Journal of Medicinal Chemistry 2024, 67, 18883-18894. DOI: 10.1021/acs.jmedchem.4c01293
5. Ma Yuan, Xie Duoli, Chen Zefeng, Shen Xinyang, Wu Xiaoqiu, Ding Feng, Ding Shijian, Pan Yufei, Li Fangfei, Lu Aiping, Zhang Ge. Advancing targeted combination chemotherapy in triple negative breast cancer: nucleolin aptamer-mediated controlled drug release. Journal of Translational Medicine 2024, 22 (1), 604. DOI: 10.1186/s12967-024-05429-8
6. Gubu Amu, Ma Yuan (co-first & co-corresponding author), Yu Sifan, Zhang Huarui, Chen Zefeng, Ni Shuaijian, Abdullah Razack, Xiao Huan, Zhang Yihao, Dai Hong, Luo Hang, Yu Yuanyuan, Wang Luyao, Jiang Hewen, Zhang Ning, Tian Yuan, Li Haitian, Lu Aiping, Zhang Baoting, Zhang Ge. Unique quinoline orientations shape the modified aptamer to sclerostin for enhanced binding affinity and bone anabolic potential. Molecular Therapy Nucleic Acids 2024, 35 (1), 102146. DOI: 10.1016/j.omtn.2024.102146
7. Zhang Huarui, Yu Sifan, Ni Shuaijian, Gubu Amu, Ma Yuan (co-first author), Zhang Yihao, Li Haitian, Wang Yuzhe, Wang Luyao, Zhang Zongkang, Yu Yuanyuan, Lyu Aiping, Zhang Baoting, Zhang Ge. A bimolecular modification strategy for developing long-lasting bone anabolic aptamer. Molecular Therapy Nucleic Acids 2023, 34 (18), 102073. DOI: 10.1016/j.omtn.2023.102073
8. Gubu Amu, Zhang Xueli, Lu Aiping, Zhang Baoting, Ma Yuan (co-corresponding author), Zhang Ge. Nucleic acid amphiphiles: synthesis, properties and applications. Molecular Therapy Nucleic Acids 2023, 33, 144-163. DOI: 10.1016/j.omtn.2023.05.022
9. Chen Zefeng, Luo Hang, Gubu Amu, Yu Sifan, Zhang Huarui, Dai Hong, Zhang Yihao, Zhang Baoting, Ma Yuan (co-corresponding author), Lu Aiping, Zhang Ge. Chemically modified aptamers for improving binding affinity to the target proteins via enhanced non-covalent bonding. Frontiers in Cell and Developmental Biology 2023, 11, 1091809. DOI: 10.3389/fcell.2023.1091809
10. Ma Yuan, Yu Yuanyuan, Zhang Baoting, Lu Aiping, Zhang Ge. Aptamer-based structural biology, computational modelling, translational research and drug discovery, Volume II. Frontiers in Cell and Developmental Biology 2023, 11, 1195372. DOI: 10.3389/fcell.2023.1195372
11. Ma Yuan, Zhang Yihao, Chen Zefeng, Tian Yuan, Zhang Ge, The Modification Strategies for Enhancing the Metabolic Stabilities and Pharmacokinetics of Aptamer Drug Candidates. In Drug Metabolism and Pharmacokinetics, Mithun Rudrapal, Ed. IntechOpen: Rijeka, 2023; p Ch. 6. DOI: 10.5772/intechopen.112756
12. Dai Hong, Abdullah Razack, Wu Xiaoqiu, Li Fangfei, Ma Yuan (co-corresponding author), Lu Aiping, Zhang Ge. Pancreatic cancer: Nucleic acid drug discovery and targeted therapy. Frontiers in Cell and Developmental Biology 2022, 10, 855474. DOI: 10.3389/fcell.2023.1195372
13. Xue Fangqin, Lin Xiao, Cai Zhixiong, Liu Xiaolong, Ma Yuan (co-corresponding author), Wu Ming. Doxifluridine-based pharmacosomes delivering mir-122 as tumor microenvironments-activated nanoplatforms for synergistic treatment of hepatocellular carcinoma. Colloids and Surfaces B: Biointerfaces 2021, 197, 111367. DOI: 10.1016/j.colsurfb.2020.111367
14. Ma Yuan, Yu Sifan, Ni Shuaijian, Zhang Baoxian, Kung Angela Chun Fai, Gao Jin, Lu Aiping, Zhang Ge. Targeting strategies for enhancing paclitaxel specificity in chemotherapy. Frontiers in Cell and Developmental Biology 2021, 9, 626910.
|
